Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges.

Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM.

Biomark Med. 2012 Aug;6(4):391-400. doi: 10.2217/bmm.12.49. Review.

PMID:
22917141
2.

Analytical aspects of molecular Alzheimer's disease biomarkers.

Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H.

Biomark Med. 2012 Aug;6(4):377-89. doi: 10.2217/bmm.12.44. Review.

PMID:
22917140
3.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E.

Biomark Med. 2012 Aug;6(4):409-17. doi: 10.2217/bmm.12.39. Review.

PMID:
22917143
4.

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.

Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, Zetterberg H, Blennow K.

Biomark Med. 2012 Aug;6(4):401-7. doi: 10.2217/bmm.12.41. Review.

PMID:
22917142
5.
6.

[A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].

Molinuevo JL, Gispert JD, Pujol J, Rojas S, Lladó A, Balasa M, Antonell A, Sánchez-Valle R, Rami L.

Rev Neurol. 2012 May 1;54(9):513-22. Spanish.

7.

[Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].

Shoji M.

Brain Nerve. 2012 May;64(5):497-504. Review. Japanese.

PMID:
22570063
8.

Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease.

Zetterberg H, Lunn MP, Herukka SK.

Biomark Med. 2012 Aug;6(4):371-6. doi: 10.2217/bmm.12.47.

PMID:
22917139
9.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
10.

Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).

Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H.

Exp Gerontol. 2009 Sep;44(9):579-85. doi: 10.1016/j.exger.2009.06.003. Epub 2009 Jun 16.

PMID:
19539742
11.

New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population.

Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein MA, Sluimer JD, Barkhof F, van der Flier WM, Scheltens P.

Dement Geriatr Cogn Disord. 2010;30(1):1-7. doi: 10.1159/000315542. Epub 2010 Jul 3.

PMID:
20606438
12.

Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?

Zetterberg H, Blennow K.

J Alzheimers Dis. 2013;33 Suppl 1:S361-9. Review.

PMID:
22710917
13.

Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.

Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Boulanghien J, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Perret-Liaudet A, Touchon J, Lehmann S.

J Alzheimers Dis. 2011;26(3):553-63. doi: 10.3233/JAD-2011-110515.

PMID:
21709372
14.

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K.

Alzheimers Dement. 2012 Jan;8(1):65-73. doi: 10.1016/j.jalz.2011.07.004. Epub 2011 Nov 2. Review.

PMID:
22047631
15.

Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.

del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C.

Biomark Med. 2012 Aug;6(4):419-30. doi: 10.2217/bmm.12.46. Review.

PMID:
22917144
16.

Fluid biomarkers for Alzheimer's disease: standardization and recent developments.

Zetterberg H, Visser PJ.

Biomark Med. 2012 Aug;6(4):363-4. doi: 10.2217/bmm.12.40. No abstract available.

17.

A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species.

Dillen L, Cools W, Vereyken L, Timmerman P.

Bioanalysis. 2011 Jan;3(1):45-55. doi: 10.4155/bio.10.163.

PMID:
21175366
18.

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.

Wallin AK, Blennow K, Andreasen N, Minthon L.

Dement Geriatr Cogn Disord. 2006;21(3):131-8. Epub 2006 Jan 2.

PMID:
16391474
19.

[Dementia: progress in diagnosis and treatment; Topics; V. Recent topics; 1. Biomarkers for Alzheimer's disease and other dementia].

Tokuda T.

Nihon Naika Gakkai Zasshi. 2011 Aug 10;100(8):2177-86. Review. Japanese. No abstract available.

PMID:
21899149

Supplemental Content

Support Center